Skyline Ventures



AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. It recently submitted an NDA for its lead drug candidate, Zalviso™.
AcelRx Pharmaceuticals, Inc.
351 Galveston Drive
Redwood City, CA 94063
Phone:650.216.3518
Fax: 650.216.6500
Advion is a leading manufacturer of high performance, small footprint mass spectrometry and chemical synthesis platforms for the life sciences. Advion’s predecessor company, which was a leading contract service organization performing high-performance mass spec analyses, was sold to Quintiles in 2011.
Advion BioSciences, Inc.
19 Brown Road
Ithaca, NY 14850 USA
Phone: 607.266.0665
Fax: 607.266.0749
Avidia was focused on discovering and developing a new class of human therapeutic proteins called Avimers™ which are derived from a family of small, naturally-occurring protein binding domains. The company was acquired by Amgen in September of 2006.
[NASDAQ: AMGN]

Avidia, Inc.
2450 Bayshore Parkway
Suite 200
Mountain View CA 94043
Phone: 650.404.2000
Fax: 650.404.2001
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on its DETERx™ platform technology, a proprietary formulation technology that makes improved, tamper-resistant forms of medications which are prone to abuse. The Company currently has two product candidates in clinical development: COL-003, a tamper-resistant form of oxycodone (the active ingredient in OxyContin®), which is entering Phase 3 development; and COL-172, a tamper-resistant form of oxymorphone, the active ingredient in Opana®. Both products have received Fast Track designation by the FDA due to their potential to address a major public health issue.
Collegium Pharmaceutical
400 Highland Corporate Drive
Cumberland, RI 02864
Phone: 401.762.2000
Crescendo Bioscience Crescendo Bioscience is commercializing Vectra DA, the only multi-biomarker blood test for rheumatoid arthritis (RA) that integrates the concentrations of 12 serum proteins associated with RA disease activity into a single objective score to help physicians make more informed treatment decisions. Vectra DA testing is performed at the Crescendo Bioscience state-of-the-art CLIA facility.
Crescendo Bioscience
341 Oyster Point Blvd
South San Francisco, CA 94080
Phone: 650.351.1354
Fax: 650.871.7155
Concert Pharmaceuticalscreates novel medicines to meet important healthcare needs by applying its DCE Platform® (Deuterated Chemical Entity Platform) to compounds with well-characterized pharmacological activity. This approach enables the company to leverage decades of pharmaceutical expertise to greatly reduce R&D risk, time and expense. The company has partnered some of its drug candidates with Avanir Pharmaceucicals, Celgene and Jazz Pharmaceuticals.
Concert Pharmaceuticals, Inc.
99 Hayden Avenue, Suite 500
Lexington, MA 02421
Phone: 781.860.0045
Fax: 781.860.8923
Dicerna Pharmaceuticals is developing novel therapeutics in multiple therapeutic areas based on Dicer substrate technology, which makes use of the RNA interference mechanism.  Dicerna’s intellectual property covers double stranded RNA molecules 26-30 base pairs in length, which are generally more potent in inducing RNA interference than the conventional 19-23 base pair sequences.
Dicerna Pharmaceuticals
480 Arsenal Street
Building 1, Suite 120
Watertown MA 02472
Phone: 617.621.8097
DiscoveRx is an innovative company that develops, manufactures, and commercializes reagents, complete cell-based assay kits, profiling and screening services as well as other turn key solutions for the drug discovery, screening, and life science markets.
DiscoveRx Corporation
42501 Albrae Street
Fremont, CA 94538
Phone: 866.448.4864
Fax: 510.979.1650
Dow was a leading formulator of prescription drugs for dermatology applications. The company was sold to Valeant Pharmaceuticals International (NYSE: VRX) in December 2008.
Dow Pharmaceutical Sciences, Inc.
1330 Redwood Way
Petaluma, CA 94954-1169
Phone: 707.793.2600
Fax: 707.793.0145

Genocea Biosciences is harnessing the power of T cell immunity to develop the next generation of vaccines, using its proprietary ATLAS™ technology platform.

Genocea Biosciences
Cambridge Discover Park
100 Acorn Park Drive, 5th Floor
Cambridge, MA 02140
Phone: 617.876.8191
Fax: 617.876.8192
Hansen Medical introduces the power of instinctive catheter movement. This revolutionary technology is designed to deliver precise three-dimensional catheter control to complex interventional procedures.
[NASDAQ: HNSN]
Hansen Medical, Inc.
800 East Middlefield Road
Mountain View, CA 94043
Phone:650.404.5800
Fax: 650.404.5901
The company seeks to correct knee misalignment through an instrumented system to guide a reproducible and precise surgical technique called high tibial osteotomy (“HTO”). iBalance was acquired by Arthrex in March, 2010.
iBalance Medical, Inc.
4900 Nautilus Ct, Suite 100
Boulder, CO 80503
Phone: 303.381.6333
Intuitive Surgical, Inc. Intuitive (ISRG) markets the Da Vinci Surgical System and is the leading company in robotics for soft tissue surgery.
Intuitive Surgical, Inc.
1266 Kifer Road, Building 101
Sunnyvale, CA 94086-5304
Phone: 408.523.2100
Fax: 408.523.1390
KAI's lead product candidate KAI-4169, is a novel agent being developed for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. In July 2012, KAI was acquired by Amgen for $315 million.
KAI Pharmaceuticals, Inc.
270 Littlefield Avenue
South San Francisco, CA 94080-6924
Phone: 650.244.1100
MAKO Surgical Corp.’s innovative robotic arm technology empowers the MAKOplasty® advantage for knee and hip procedures. The RIO® Robotic Arm Interactive Orthopedic System and enabling RESTORIS® implant designs, allow surgeons to achieve a new level of accuracy, precision, and confidence to patient-specific treatment of painful knee and hip conditions that may restore patient mobility and an active lifestyle. In September 2013, MAKO announced it had signed a definitive agreement to be acquired by Stryker for $1.65 billion.
[NASDAQ: MAKO]
MAKO Surgical Corp.
2555 Davie Road
Ft. Lauderdale, FL 33317
Phone: 954.927.2044
Fax: 954.927.0446
MAP is developing Levadex®, and inhaled drug for migraine headaches. The company was acquired by Allergan in 2013 for $958 million.
[NASDAQ: MAPP]
MAP Pharmaceuticals
2400 Bayshore Parkway, Suite 200
Mountain View, CA 94043
Phone:650.386.3100
Fax:650.386.3101
Medivance was the leading company in therapeutic hypothermia. It is the only company to produce a practical solution that uses consumables and equipment for the non-invasive production of therapeutic hypothermia. The Company was acquired by Bard [NYSE: BCR] in October of 2011 for $250 million.
Medivance®, Inc.
321 South Taylor Avenue, Suite 200
Louisville, CO 80027
Phone: 303.926.1917
Fax: 303.926.1924
NimbleGen manufactured high-density, fully-custom microarrays for any sequences of any genome, up to 60-mers in length. The company was purchased by Roche Holdings in 2007 for $272.5 million.
NimbleGen Systems, Inc.
504 South Rosa Road
Madison, WI 53719
Phone: 608.218.7600
Fax: 608.218.7601
NovaCardia was a product-focused pharmaceutical company developing and commercializing a portfolio of novel small molecule drugs with an initial focus on the acute cardiac care marketplace. The company was acquired by Merck & Co. in September of 2007 for $350 million.
[NYSE: MRK]
NovaCardia, Inc.
12651 High Bluff Drive
Suite 200
San Diego, CA 92130
Phone:858.509.0455
Fax:858.509.0456
Theravance, Inc. Theravance (THRX) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The Company's key programs include: RELVAR™ ELLIPTA™or BREO™ ELLIPTA™(FF/VI), ANORO™ ELLIPTA™ (UMEC/VI) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and our oral Peripheral Mu Opioid Receptor Antagonist program.
Theravance, Inc.
901 Gateway Boulevard
South San Francisco, CA 94080
Phone: 650.808.6000
Proteon is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for orphan indications that improve vascular access for patients with chronic kidney disease who are undergoing hemodialysis. In a recent Phase 2 study, Proteon’s drug candidate PRT-201 improved the percentage of arteriovenous fistulas for vascular access that developed adequate blood flow for dialysis and reduced the percentage that developed a thrombosis or required an intervention procedure within one year.
Proteon Therapeutics, Inc.
4420 Madison Avenue
Suite 180
Kansas City, MO 64111
Phone: 816.531.0028
Fax: 816.531.3079
SI Bone has developed proprietary surgical devices to fixate the sacroiliac (SI) joint using minimally invasive techniques. Orthopedists are increasingly realizing that sacroiliac joint arthritis is responsible for a large percentage of lower back pain. Conventional methods to treat and fuse the SI joint are highly invasive.
SI-BONE, Inc.
3055 Olin Avenue
Ste. 2200
San Jose, CA 95128
Phone: 408.207.0700
Fax: 408.557.8312
Sirtris is focused on discovering and developing proprietary, orally available drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Its drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of sirtuins, a recently discovered class of enzymes that control the aging process. The company was acquired by GlaxoSmithKline for $720 million in June 2008.
[NASDAQ: SIRT]
Sirtris Pharmaceuticals
200 Technology Square
Cambridge, MA 02139
Phone: 617.252.6920
Fax: 617.252.6924
Spinal Motion is in late stage US clinical trials of its artificial discs for treating patients with degenerative disc disease in the lumbar and cervical spine. Its products were invented in South Africa and are on the market there with excellent results.
SpinalMotion, Inc.
201 San Antonio Circle
Suite 115, Building B
Mountain View, CA 94040
Phone: 650.947.3472
Fax: 650.947.3473
Sutro Biopharma, Inc. has the only scalable biochemical protein synthesis platform. It is using its platform to develop a new generation of multi-functional antibody drug conjugate combination therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies. These therapeutics will significantly extend the clinical impact of current oncology therapeutic approaches, and are beyond what can be envisioned with current (cell-based) expression technologies.
Sutro Biopharma
310 Utah Ave
Suite 150
South San Francisco, CA 94080
Phone: 650.392.8412
Fax: 650.872.8924
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multi-drug resistant (MDR) infections. Its lead product candidate, eravacycline, as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant (MDR) infections, including MDR Gram-negative bacteria, and has recently entered Phase 3 testing.
Tetraphase Pharmaceuticals
480 Arsenal Street, Ste 110
Watertown, MA 02472
Phone: 617.715.3600
Fax: 617.926.3557
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. XenoPort is currently commercializing Horizant® (gabapentin enacarbil) Extended-Release Tablets, its first approved product in the United States, and developing a novel fumaric acid ester product candidate, XP23829, as a potential treatment for relapsing-remitting multiple sclerosis and/or psoriasis. Regnite is being marketed in Japan by Astellas Pharma Inc. XenoPort's pipeline of product candidates also includes potential treatments for patients with spasticity related to spinal cord injury and Parkinson's disease.
[NASDAQ: XNPT]
XenoPort, Inc.
3410 Central Expressway
Santa Clara, CA 95051
Phone: 408.616.7200
Fax: 408.616.7210

HomeAbout UsOur TeamOur PortfolioWhat We Look ForContact Us

2012 Copyright © Skyline Management LLC
web design by San Francisco Web Design & Database